Accuracy and Clinical Correlates of Two Different Methods for Chromogranin A Assay in Neuroendocrine Tumors
Authors:
- 1 October 2004
- journal article
- research article
- Published by SAGE Publications in The International Journal of Biological Markers
- Vol. 19 (4) , 295-304
Abstract
Measurement of chromogranin A (CgA) plays a major role in the management of neuroendocrine tumors (NET); however, reliable assaying of CgA is made difficult by the rapid hydrolysis following its release into the bloodstream. This study was aimed at the assessment of two assays for CgA in NET patients. CgA was measured in 93 patients by means of an enzyme-linked immunosorbent assay (ELISA) and an immunoradiometric assay (IRMA). The specificity and sensitivity of CgA were evaluated in relation to tumor histology. The clinical accuracy of the two assays was evaluated by receiver-operating characteristic (ROC) curve analysis. Regression analysis demonstrated different immunoreactivity for CgA of the antibodies used in the two kits (r=0.61). The two assays had different accuracy also in classifying patients according to their clinical condition (91% vs 64% specificity and 79% vs 79% sensitivity for the ELISA and IRMA assay, respectively) and tumor histology (81% vs 85% sensitivity for the ELISA and IRMA assays, respectively, in carcinoids; 92% vs 67% sensitivity for the ELISA and IRMA assays, respectively, in pancreatic islet cell tumors). The different clinical accuracy of the two assays was confirmed by the ROC analysis (AUC=0.90 vs AUC=0.87 for the ELISA and IRMA assays, respectively). In conclusion, because of the poor standardization of the commercially available measurement tools the clinical accuracy of CgA measurement depends on the assay used. This makes it difficult to compare CgA values measured with different kits and affects the clinical accuracy of the different assays for CgA.Keywords
This publication has 41 references indexed in Scilit:
- The Chromogranin–Secretogranin FamilyNew England Journal of Medicine, 2003
- Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumoursBritish Journal of Cancer, 1998
- Chromogranin a Measurement in Neuroendocrine TumorsThe International Journal of Biological Markers, 1998
- Phosphorylation and O-Glycosylation Sites of Bovine Chromogranin A from Adrenal Medullary Chromaffin Granules and Their Relationship with Biological ActivitiesJournal of Biological Chemistry, 1997
- Molecular Cloning and Characterization of NESP55, a Novel Chromogranin-like Precursor of a Peptide with 5-HT1B Receptor Antagonist ActivityJournal of Biological Chemistry, 1997
- Intracellular and extracellular processing of chromogranin AEuropean Journal of Biochemistry, 1993
- The granin-(chromogranin/secretogranin) familyTrends in Biochemical Sciences, 1991
- Chromogranin A: Posttranslational Modifications in Secretory GranulesEndocrinology, 1991
- Proteolytic processing of chromogranin A in purified insulin granules. Formation of a 20 kDa N-terminal fragment (betagranin) by the concerted action of a Ca2+-dependent endopeptidase and carboxypeptidase H (EC 3.4.17.10)Biochemical Journal, 1987
- Secretion of Chromogranin A by Peptide-Producing Endocrine NeoplasmsNew England Journal of Medicine, 1986